Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) A kit for measuring the thrombin generation in a sample, said kit comprising

(i) a lyophilized tissue factor (TF)/phospholipid (PL)-complex; and

(ii) a lyophilized mixture comprising $CaCl_2$ and a thrombin substrate ~~comprising~~ that comprises a fluorescent label, where said thrombin substrate that comprises the fluorescent label is Z-Gly-Gly-Arg-AMC; wherein the lyophilized mixture is prepared from a solution comprising the substrate, $CaCl_2$ and DMSO and forms a clear solution when dissolved in water, and further, wherein the amount of water that dissolves the lyophilized mixture to form the clear solution provides a concentration of 1 mM thrombin substrate and 15 mM $CaCl_2$.

2. (original) The kit according to claim 1, wherein the concentration of TF in the lyophilized TF/PL-complex ranges from about 5 to about 1000 pM.

3. (original) The kit according to claim 1, wherein the concentration of PL in the lyophilized TF/PL-complex ranges from about 1 to about 100 μM.

4. (original) The kit according to claim 1, wherein said TF or at least a functional part thereof is of natural or recombinant origin.

5. (original) The kit according to claim 1, wherein said PL is of natural or synthetic origin.

6. (original) The kit according to claim 1, wherein said PL is selected from the group consisting of phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE) and mixtures thereof.

7. (original) The kit according to claim 6, wherein the weight ratio of PC/PS is in the range of from about 60/40 to about 95/5.

8. (original) The kit according to claim 6, wherein the weight ratio of PC/PS/PE is in the range of from about 60/20/20 to about 78/17/5, based on the total amount of phospholipids.

9. (cancelled)

10. (original) The kit according to claim 1, further comprising at least one thrombin standard.

11. (original) The kit according to claim 1, wherein the lyophilized TF/PL-complex is immobilized onto a support.

12. (previously presented) The kit according to claim 1, wherein the lyophilized mixture comprising $CaCl_2$ and the thrombin-substrate comprising a fluorescent label is immobilized onto a support.

13. (original) The kit according to claim 11 or 12, wherein the support is the inner surface of a vial or wells of an ELISA plate or strip.

14-21. (cancelled)

22. (currently amended) A method for measuring the thrombin generation in a whole blood or plasma sample, comprising the steps of:

(a) providing a lyophilized tissue factor (TF)/phospholipid (PL)-complex and a lyophilized mixture containing a thrombin-substrate that comprises ~~comprising~~ a fluorescent label, where said thrombin substrate that comprises the fluorescent label is Z-Gly-Gly-Arg-AMC, and $CaCl_2$, wherein the lyophilized mixture is prepared from a solution comprising the thrombin substrate, $CaCl_2$ and DMSO and forms a clear solution when dissolved in water,

wherein the amount of water that dissolves the lyophilized mixture to form the clear solution provides a concentration of 1 mM thrombin substrate and 15 mM $CaCl_2$;

(b) contacting the whole blood or plasma sample with said lyophilized TF/PL-complex and said lyophilized mixture containing thrombin-substrate and $CaCl_2$; and

(c) measuring the thrombin generation in said sample.

23. (currently amended) The method according to claim 22, wherein the sample is a cell-free plasma sample ~~selected from the group consisting of whole blood, plasma and mixtures containing purified proteins from natural, synthetic or recombinant origin having haemostatic activity~~.

24. (cancelled)